Bioxyne Limited (ASX:BXN)
Australia · Delayed Price · Currency is AUD 0.0550
-0.0010 (-1.79%)
At close: Mar 12, 2026
Bioxyne Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Operating Revenue | 47.18 | 28.43 | 9.33 | 5.15 | 0.46 | 2.11 |
Other Revenue | 0.78 | 0.85 | 0.32 | 0.14 | - | 0.09 |
| 47.95 | 29.28 | 9.64 | 5.3 | 0.46 | 2.2 | |
Revenue Growth (YoY) | 178.16% | 203.66% | 81.97% | 1042.88% | -78.97% | -5.61% |
Cost of Revenue | 28.27 | 18.1 | 5.93 | 3.73 | 0.33 | 1.25 |
Gross Profit | 19.69 | 11.18 | 3.72 | 1.57 | 0.13 | 0.95 |
Selling, General & Admin | 7.29 | 4.23 | 3.64 | 2.69 | 0.49 | 1.19 |
Research & Development | 0.17 | 0.17 | 0.72 | - | - | 0.09 |
Operating Expenses | 9.78 | 6.08 | 4.85 | 3.38 | 0.59 | 1.32 |
Operating Income | 9.91 | 5.1 | -1.13 | -1.82 | -0.45 | -0.37 |
Interest Expense | -0.04 | - | - | - | - | -0 |
Interest & Investment Income | 0.02 | 0.02 | 0.02 | 0 | - | 0.02 |
Currency Exchange Gain (Loss) | - | - | - | 0.04 | 0 | -0.03 |
Other Non Operating Income (Expenses) | -0.69 | -0.22 | -0.21 | -0.04 | -0 | -0.1 |
EBT Excluding Unusual Items | 9.2 | 4.9 | -1.32 | -1.82 | -0.45 | -0.5 |
Impairment of Goodwill | - | - | -11.57 | - | - | - |
Gain (Loss) on Sale of Assets | - | - | -0.08 | - | - | - |
Asset Writedown | -0.26 | - | - | -0.1 | -0.04 | - |
Pretax Income | 8.94 | 4.9 | -12.97 | -1.92 | -0.49 | -0.5 |
Earnings From Continuing Operations | 8.94 | 4.9 | -12.97 | -1.92 | -0.49 | -0.5 |
Earnings From Discontinued Operations | 0.04 | - | -0.53 | -0.05 | - | - |
Net Income to Company | 8.99 | 4.9 | -13.5 | -1.96 | -0.49 | -0.5 |
Minority Interest in Earnings | -0.02 | - | 0.18 | 0.02 | - | - |
Net Income | 8.97 | 4.9 | -13.33 | -1.94 | -0.49 | -0.5 |
Net Income to Common | 8.97 | 4.9 | -13.33 | -1.94 | -0.49 | -0.5 |
Net Income Growth | 300.76% | - | - | - | - | - |
Shares Outstanding (Basic) | 2,120 | 2,078 | 1,930 | 1,344 | 732 | 640 |
Shares Outstanding (Diluted) | 2,259 | 2,150 | 1,930 | 1,344 | 732 | 640 |
Shares Change (YoY) | 11.95% | 11.36% | 43.61% | 83.52% | 14.42% | - |
EPS (Basic) | 0.00 | 0.00 | -0.01 | -0.00 | -0.00 | -0.00 |
EPS (Diluted) | 0.00 | 0.00 | -0.01 | -0.00 | -0.00 | -0.00 |
EPS Growth | 259.93% | - | - | - | - | - |
Free Cash Flow | 0.28 | 4.21 | -3.74 | -1.19 | -0.57 | 0.05 |
Free Cash Flow Per Share | - | 0.00 | -0.00 | -0.00 | -0.00 | - |
Gross Margin | 41.05% | 38.17% | 38.53% | 29.55% | 29.10% | 43.13% |
Operating Margin | 20.66% | 17.41% | -11.75% | -34.32% | -97.72% | -16.97% |
Profit Margin | 18.70% | 16.74% | -138.19% | -36.61% | -106.55% | -22.49% |
Free Cash Flow Margin | 0.59% | 14.37% | -38.77% | -22.45% | -122.27% | 2.41% |
EBITDA | 10.2 | 5.4 | -1.08 | -1.71 | -0.42 | -0.36 |
EBITDA Margin | 21.27% | 18.45% | -11.22% | -32.25% | -91.09% | -16.17% |
D&A For EBITDA | 0.29 | 0.3 | 0.05 | 0.11 | 0.03 | 0.02 |
EBIT | 9.91 | 5.1 | -1.13 | -1.82 | -0.45 | -0.37 |
EBIT Margin | 20.66% | 17.41% | -11.75% | -34.32% | -97.72% | -16.97% |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.